Ventyx Biosciences Net Income
| VTYX Stock | USD 13.94 0.02 0.14% |
As of the 12th of February 2026, Ventyx Biosciences has the Semi Deviation of 3.34, risk adjusted performance of 0.1043, and Coefficient Of Variation of 830.6. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ventyx Biosciences, as well as the relationship between them.
Ventyx Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ventyx Biosciences' valuation are provided below:We have found one hundred twenty available fundamental trend indicators for Ventyx Biosciences, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Ventyx Biosciences current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 163.8 M in 2026. Enterprise Value is likely to drop to about 145.9 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -121.6 M | -127.7 M | |
| Net Loss | -97.6 M | -92.7 M | |
| Net Loss | -121.6 M | -127.7 M | |
| Net Loss | (2.27) | (2.38) | |
| Net Income Per E B T | 0.93 | 0.82 |
Ventyx | Net Income | Build AI portfolio with Ventyx Stock |
The evolution of Net Income for Ventyx Biosciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Ventyx Biosciences compares to historical norms and industry peers.
Latest Ventyx Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Ventyx Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ventyx Biosciences financial statement analysis. It represents the amount of money remaining after all of Ventyx Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ventyx Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ventyx Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (135.12 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ventyx Net Income Regression Statistics
| Arithmetic Mean | (49,556,476) | |
| Coefficient Of Variation | (128.22) | |
| Mean Deviation | 55,554,969 | |
| Median | (4,473,000) | |
| Standard Deviation | 63,541,389 | |
| Sample Variance | 4037.5T | |
| Range | 188.5M | |
| R-Value | (0.82) | |
| Mean Square Error | 1378.8T | |
| R-Squared | 0.68 | |
| Significance | 0.000047 | |
| Slope | (10,375,166) | |
| Total Sum of Squares | 64600.1T |
Ventyx Net Income History
Other Fundumenentals of Ventyx Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ventyx Biosciences Net Income component correlations
Ventyx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ventyx Biosciences is extremely important. It helps to project a fair market value of Ventyx Stock properly, considering its historical fundamentals such as Net Income. Since Ventyx Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ventyx Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ventyx Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ventyx Biosciences. If investors know Ventyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ventyx Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Ventyx Biosciences is measured differently than its book value, which is the value of Ventyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ventyx Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ventyx Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ventyx Biosciences' market value can be influenced by many factors that don't directly affect Ventyx Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ventyx Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ventyx Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Ventyx Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Ventyx Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ventyx Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ventyx Biosciences.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Ventyx Biosciences on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Ventyx Biosciences or generate 0.0% return on investment in Ventyx Biosciences over 90 days. Ventyx Biosciences is related to or competes with Olema Pharmaceuticals, Regenxbio, Corvus Pharmaceuticals, Gossamer Bio, Absci Corp, Verastem, and Prothena Plc. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to addr... More
Ventyx Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ventyx Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ventyx Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.47 | |||
| Information Ratio | 0.1054 | |||
| Maximum Drawdown | 37.04 | |||
| Value At Risk | (6.33) | |||
| Potential Upside | 9.0 |
Ventyx Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ventyx Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ventyx Biosciences' standard deviation. In reality, there are many statistical measures that can use Ventyx Biosciences historical prices to predict the future Ventyx Biosciences' volatility.| Risk Adjusted Performance | 0.1043 | |||
| Jensen Alpha | 0.8317 | |||
| Total Risk Alpha | 0.0076 | |||
| Sortino Ratio | 0.1623 | |||
| Treynor Ratio | (5.66) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ventyx Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ventyx Biosciences February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1043 | |||
| Market Risk Adjusted Performance | (5.65) | |||
| Mean Deviation | 3.49 | |||
| Semi Deviation | 3.34 | |||
| Downside Deviation | 4.47 | |||
| Coefficient Of Variation | 830.6 | |||
| Standard Deviation | 6.88 | |||
| Variance | 47.32 | |||
| Information Ratio | 0.1054 | |||
| Jensen Alpha | 0.8317 | |||
| Total Risk Alpha | 0.0076 | |||
| Sortino Ratio | 0.1623 | |||
| Treynor Ratio | (5.66) | |||
| Maximum Drawdown | 37.04 | |||
| Value At Risk | (6.33) | |||
| Potential Upside | 9.0 | |||
| Downside Variance | 19.95 | |||
| Semi Variance | 11.17 | |||
| Expected Short fall | (4.00) | |||
| Skewness | 3.08 | |||
| Kurtosis | 14.5 |
Ventyx Biosciences Backtested Returns
Ventyx Biosciences appears to be slightly risky, given 3 months investment horizon. Ventyx Biosciences owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. By inspecting Ventyx Biosciences' technical indicators, you can evaluate if the expected return of 0.91% is justified by implied risk. Please review Ventyx Biosciences' Risk Adjusted Performance of 0.1043, semi deviation of 3.34, and Coefficient Of Variation of 830.6 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ventyx Biosciences holds a performance score of 10. The entity has a beta of -0.14, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Ventyx Biosciences are expected to decrease at a much lower rate. During the bear market, Ventyx Biosciences is likely to outperform the market. Please check Ventyx Biosciences' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Ventyx Biosciences' existing price patterns will revert.
Auto-correlation | -0.39 |
Poor reverse predictability
Ventyx Biosciences has poor reverse predictability. Overlapping area represents the amount of predictability between Ventyx Biosciences time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ventyx Biosciences price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Ventyx Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 4.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ventyx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ventyx Biosciences reported net income of (135.12 Million). This is 139.59% lower than that of the Pharmaceuticals sector and 292.91% lower than that of the Health Care industry. The net income for all United States stocks is 123.66% higher than that of the company.
Ventyx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ventyx Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ventyx Biosciences could also be used in its relative valuation, which is a method of valuing Ventyx Biosciences by comparing valuation metrics of similar companies.Ventyx Biosciences is currently under evaluation in net income category among its peers.
Ventyx Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ventyx Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ventyx Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Ventyx Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Ventyx Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ventyx Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ventyx Biosciences' value.| Shares | Ikarian Capital, Llc | 2025-06-30 | 967.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 945.2 K | Sectoral Asset Management Inc | 2025-06-30 | 931.6 K | Bank Of America Corp | 2025-06-30 | 838.4 K | Monaco Asset Management | 2025-06-30 | 761.9 K | Aqr Capital Management Llc | 2025-06-30 | 729.9 K | Geode Capital Management, Llc | 2025-06-30 | 711.8 K | Goldman Sachs Group Inc | 2025-06-30 | 580.4 K | Sphera Funds Management Ltd. | 2025-06-30 | 555.8 K | Point72 Asset Management, L.p. | 2025-06-30 | 5.9 M | Affinity Asset Advisors, Llc | 2025-06-30 | 4.5 M |
Ventyx Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 818.66 M | ||||
| Shares Outstanding | 71.75 M | ||||
| Shares Owned By Insiders | 4.21 % | ||||
| Shares Owned By Institutions | 69.15 % | ||||
| Number Of Shares Shorted | 4.31 M | ||||
| Price To Book | 5.23 X | ||||
| EBITDA | (147.1 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 250.45 M | ||||
| Cash Per Share | 4.92 X | ||||
| Total Debt | 10.79 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.27 X | ||||
| Book Value Per Share | 2.68 X | ||||
| Cash Flow From Operations | (130.87 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 14.14 | ||||
| Number Of Employees | 83 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 1 B | ||||
| Total Asset | 276.56 M | ||||
| Retained Earnings | (554.31 M) | ||||
| Working Capital | 216.85 M | ||||
| Net Asset | 276.56 M |
About Ventyx Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ventyx Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ventyx Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ventyx Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.